7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 
      
    		                                                          
      operating activities:
    		                                                          
      net income
    		5,432,000 -4,847,000 4,812,000 16,041,000 -143,466,000 18,886,000 8,979,000 24,870,000 10,858,000 25,763,000 -19,536,000 -10,102,000 -693,000 19,876,000 6,828,000 -5,130,000 17,660,000 19,081,000 10,369,000 14,515,000 130,119,000 -7,270,000 8,159,000 -4,888,000 -6,087,000 2,730,000 -2,771,000 8,285,000 -640,000 2,564,000 -10,680,000 4,595,000 -7,597,000 -19,743,000 -19,866,000 -3,972,000 -22,165,000 -7,958,000 -3,854,000 -2,498,000 3,086,000 8,000 1,260,000 5,802,000 -3,004,000 -5,037,000 -11,477,000 -11,956,000 -14,784,000 -14,031,000 -23,138,000 -15,745,000 -8,296,000 -11,894,000 -15,283,000 -9,508,000 -8,762,000 -9,775,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                          
      goodwill impairment
    		   0                                                       
      indefinite-lived intangible asset impairment
    		                                                          
      investment impairment
    		                                                          
      deferred taxes
    		8,072,000 752,000 1,397,000 3,508,000 1,115,000 12,535,000 3,463,000 6,601,000 4,914,000 11,442,000 -7,342,000 -10,840,000 702,000 2,164,000 29,000 -2,081,000 5,340,000 5,867,000 1,746,000                                        
      depreciation of fixed assets and amortization of intangible assets
    		21,191,000 27,322,000 21,168,000 21,243,000 20,253,000 18,863,000 18,426,000 18,485,000 18,433,000 19,054,000 19,602,000 30,406,000 20,198,000 20,864,000 20,033,000 13,070,000 5,730,000 4,897,000 4,851,000 5,061,000 5,037,000 4,989,000 4,821,000 5,090,000 5,605,000                                  
      amortization of debt issuance costs
    		626,000 849,000 845,000 846,000 840,000 763,000 681,000 685,000 683,000 691,000 937,000 1,443,000 904,000 874,000 1,179,000 778,000 666,000 659,000 651,000  629,000 444,000 439,000                                    
      amortization of debt discount
    		56,000 23,000 22,000 22,000 23,000 23,000 24,000 24,000 25,000 28,000 675,000 700,000 695,000 706,000 706,000 5,907,000 5,844,000 5,744,000 5,657,000 5,570,000 5,430,000 3,660,000 3,594,000 3,530,000 3,467,000 3,404,000 3,345,000 3,287,000 3,229,000 3,170,000 3,113,000 3,058,000 3,003,000 2,951,000 1,411,000 1,022,000 1,022,000 1,022,000 1,022,000 1,022,000 1,022,000 1,023,000 1,035,000 1,035,000 1,035,000 1,034,000 1,035,000 1,035,000 1,034,000 1,035,000 855,000        
      gain on early extinguishment of debt
    		                                                          
      stock-based compensation
    		13,978,000 15,472,000 14,553,000 12,266,000 13,230,000 12,524,000 13,151,000 12,420,000 12,530,000 10,955,000 11,990,000 12,677,000 12,682,000 11,544,000 11,189,000 10,890,000 10,785,000 10,461,000 10,110,000 10,896,000 10,954,000 9,223,000 8,847,000 9,189,000 9,244,000 7,783,000 7,434,000 8,186,000 8,107,000 7,047,000 8,385,000 8,194,000 8,663,000 7,344,000 7,400,000 7,732,000 7,361,000 7,665,000 8,490,000 9,728,000 8,827,000 7,296,000 7,517,000 7,623,000 7,687,000 5,537,000 3,975,000 3,286,000 3,777,000 2,225,000 2,225,000 1,469,000 1,039,000 712,000     
      changes in contingent consideration
    		625,000 -357,000 -2,675,000 1,084,000 -3,244,000 1,509,000 -3,806,000 423,000 2,793,000 -18,258,000 11,618,000 -6,082,000 -1,043,000 -21,280,000 -1,071,000 1,158,000 -1,159,000 139,000 -1,127,000 6,764,000 752,000 1,562,000 -3,874,000 9,345,000                                   
      other net gains
    		                                                          
      changes in operating assets and liabilities:
    		                                                          
      accounts receivable
    		-897,000 -9,605,000 8,559,000 -12,651,000 4,127,000 -3,141,000 3,917,000 -8,599,000 2,123,000 -5,875,000 5,192,000 -4,926,000 -2,366,000 998,000 4,215,000 -13,504,000 18,382,000 -15,774,000 462,000 -6,902,000 -2,131,000 -5,025,000 8,542,000 -4,957,000 -1,426,000 -375,000 -1,766,000 -3,734,000 1,375,000 -4,438,000 798,000 -4,637,000 446,000 235,000 2,235,000 -3,172,000 1,886,000 -2,750,000 -46,000 64,000 -1,638,000 230,000 -2,145,000 -1,849,000 28,000 -4,576,000 -1,379,000 -4,819,000           
      inventories
    		-9,513,000 -14,399,000 -8,472,000 -13,417,000 -8,427,000 -6,657,000 7,572,000 -7,833,000 -4,390,000 847,000 3,086,000 735,000 3,789,000 3,074,000 -5,112,000 -1,907,000 -1,945,000 -658,000 43,000 3,893,000 -1,852,000 -7,024,000 -1,370,000 1,941,000 -7,448,000 -4,059,000 1,540,000 -3,684,000 -2,831,000 -2,010,000 1,368,000 -2,299,000 -5,510,000 -3,291,000 967,000 6,198,000 23,440,000 2,828,000 -2,099,000 -5,513,000 -7,363,000 -12,505,000 -7,001,000 -5,601,000 -4,468,000 -3,830,000 193,000 49,000   1,317,000      -106,000 -173,000 
      prepaid expenses and other assets
    		4,724,000 -11,524,000 -7,111,000 -1,022,000 -5,029,000 -2,206,000 897,000 -2,653,000 -2,617,000 -2,443,000 -1,926,000 -2,131,000 2,665,000 1,027,000 -4,260,000 235,000 1,851,000 -1,198,000 254,000 -357,000 1,319,000 1,973,000 -3,674,000 -1,434,000 -1,288,000 481,000 -1,644,000 -1,816,000 -1,514,000 1,312,000 -1,210,000 -258,000 1,885,000 -1,202,000 3,051,000 825,000 -4,294,000 3,009,000 -2,917,000 -1,360,000    -751,000 -364,000 -569,000 237,000 -334,000     64,000 366,000     
      accounts payable
    		-12,013,000 6,880,000 2,464,000 -325,000 637,000 9,748,000 -6,976,000 -1,072,000 -7,695,000 7,055,000 2,628,000 1,591,000 -577,000 -847,000 6,105,000 -9,437,000 -2,981,000 3,507,000 -1,351,000 -2,195,000 2,400,000 -6,385,000 2,868,000 -2,651,000 2,150,000 121,000 -1,442,000 827,000 1,426,000 -2,932,000 106,000                          -298,000 258,000 
      accrued expenses and income taxes payable
    		7,530,000 -19,377,000 4,702,000 -826,000 11,185,000 -2,110,000 3,471,000 4,117,000 4,615,000 -5,651,000 -25,120,000 3,703,000 -4,522,000 -9,877,000 -9,161,000 22,485,000 1,106,000 -113,000 -18,027,000 10,455,000 5,014,000 3,232,000 -24,700,000 16,209,000 2,160,000 7,010,000 -5,166,000 5,274,000 2,232,000 5,320,000 -7,623,000                            
      other liabilities
    		-5,826,000 9,823,000 1,082,000 3,909,000 -405,000 -19,000 -771,000 394,000 -238,000 -143,000 421,000 -1,179,000 144,000 409,000 70,000 1,767,000 -1,032,000 737,000 -1,701,000 -797,000 1,382,000 -1,879,000 -1,173,000 -5,904,000 -577,000 -194,000 -51,000 85,000 487,000 434,000 -109,000 -556,000 -1,519,000 -419,000 -1,061,000 -1,097,000 -1,574,000 3,177,000 -419,000 4,796,000 952,000 9,000 29,000 210,000 879,000 985,000 278,000 312,000 203,000 82,000 450,000    -2,170,000 1,405,000 -433,000 1,225,000 
      net cash from operating activities
    		60,834,000 12,012,000 35,459,000 33,132,000 53,920,000 53,236,000 49,101,000 47,584,000 44,438,000 43,499,000 19,128,000 42,037,000 42,654,000 29,806,000 30,777,000 23,215,000 60,287,000 30,134,000 12,081,000 46,667,000 39,781,000 -15,624,000 6,208,000 25,904,000 18,354,000 22,763,000 3,499,000 21,220,000 16,629,000 13,710,000 -2,689,000 16,931,000 -2,808,000 3,656,000 6,000 17,349,000 11,684,000 7,541,000 -3,121,000 17,035,000 2,817,000 8,651,000 493,000 13,011,000 8,976,000 8,218,000 -4,736,000 -6,280,000         -10,923,000 -3,987,000 
      investing activities:
    		                                                          
      acquisition of gq bio therapeutics gmbh
    		0 0 -16,702,000                                                        
      purchases of fixed assets
    		-3,870,000 -2,697,000 -8,548,000 -2,118,000 -4,092,000 -1,590,000 -2,836,000 -1,798,000 -3,394,000 -3,404,000 -6,565,000 -5,492,000 -5,181,000 -11,735,000 -7,668,000 -9,166,000 -13,076,000 -10,551,000 -13,073,000 -14,408,000 -7,763,000 -8,906,000 -6,724,000 -4,497,000 -1,592,000 -2,052,000 -2,018,000 -2,243,000 -4,453,000 -2,634,000 -5,184,000 -5,076,000 -5,419,000 -5,155,000 -3,616,000 -4,882,000 -3,906,000 -8,868,000 -7,053,000 -9,124,000 -9,604,000 -13,305,000 -9,237,000 -7,112,000 -4,946,000 -6,023,000 -3,808,000            
      purchases of available-for-sale investments
    		-38,765,000 -5,056,000 -69,629,000 -45,195,000 -101,236,000 -49,726,000 -56,055,000 -25,926,000 -42,173,000 -20,012,000 -49,497,000 -68,259,000 -131,785,000 -32,040,000 -155,601,000 -97,996,000                                           
      sales of available-for-sale investments
    		86,249,000 71,166,000 69,250,000 46,945,000 53,165,000 36,101,000 43,361,000 36,098,000 41,225,000 33,500,000 126,245,000 84,940,000 89,700,000   598,122,000                                           
      purchases of debt investments
    		0                                                          
      net cash from investing activities
    		43,614,000 62,163,000 -25,629,000 -368,000 -52,163,000 -15,215,000 -15,530,000 8,374,000 -4,342,000 7,326,000 66,183,000 11,189,000 -47,516,000 19,161,000 -208,019,000   3,033,000 -55,664,000 -82,317,000 -202,847,000 36,123,000 -28,566,000 -30,795,000 5,625,000 -181,799,000 78,481,000 -123,163,000 94,459,000 59,573,000 -10,293,000 8,699,000 -27,478,000 -61,150,000 -143,836,000 -6,917,000 -13,320,000 -19,642,000 -21,875,000 7,255,000 -6,840,000 -19,483,000 -1,163,000 4,017,000 -101,801,000 -30,574,000 9,019,000 14,599,000           
      financing activities:
    		                                                          
      proceeds from exercises of stock options
    		       0 26,000 1,580,000 333,000 905,000 1,601,000 10,857,000 11,024,000 4,795,000 3,052,000 5,672,000 10,325,000 9,238,000 29,627,000 2,898,000 3,455,000 3,478,000 1,423,000 2,467,000 1,101,000                                
      proceeds from shares issued under employee stock purchase plan
    		0   934,000 0    -1,000    -1,000    0   1,125,000 0   1,132,000 0   832,000 0   806,000 0   500,000 0   898,000 0                  
      payment of employee withholding taxes on restricted stock unit vests
    		-8,000 -5,285,000 -181,000 -77,000 -32,000 -378,000 -4,000                                                    
      purchase of treasury stock, inclusive of broker fees
    		-50,041,000                                                          
      proceeds from 2029 convertible senior notes
    		   0 0                                                      
      proceeds from revolving credit facility
    		                                                          
      repayment of 2024 convertible senior notes
    		   0 0       0 0 0 -192,609,000                                            
      repayment of 2025 convertible senior notes
    		   0 0                                                      
      repayment of term loan a facility
    		-98,749,000 -3,750,000 -2,813,000 -2,812,000 -2,813,000 -2,812,000 -2,813,000  -27,812,000                                                  
      repayment of revolving credit facility
    		                                                          
      purchase of capped call transactions
    		   0 0                                                      
      payment of debt issuance and financing costs
    		   0 0   0 0 0 -1,163,000         0            0 0 0 -11,000,000             0           
      net cash from financing activities
    		-257,476,000 -57,505,000 -2,994,000 -1,955,000 -2,845,000 24,980,000 -2,817,000 -1,779,000 -27,787,000 440,000 -153,905,000  -7,775,000 -153,657,000 -181,585,000 361,409,000 3,052,000 5,908,000 10,325,000 10,363,000 209,758,000 3,464,000 -1,281,000 -2,020,000 1,423,000 3,737,000 530,000 3,528,000 2,982,000 2,025,000 419,000 2,280,000 2,688,000 2,338,000 216,856,000 1,070,000 769,000 2,381,000 3,041,000 2,172,000 1,823,000 2,657,000 4,047,000 2,736,000 2,381,000 111,794,000 1,964,000 813,000 979,000 1,187,000 86,186,000 250,000   49,130,000 11,000 0 38,017,000 
      effect of exchange rate changes on cash and cash equivalents
    		133,000                                                          
      net increase in cash and cash equivalents
    		-152,895,000 16,874,000 6,836,000 30,809,000 -1,088,000 63,001,000 30,754,000     -5,285,000 -12,637,000   451,542,000 28,262,000   -25,287,000 46,692,000 23,963,000 -23,639,000 -6,911,000 25,402,000 -155,299,000 82,510,000 -98,415,000 114,070,000 75,308,000 -12,563,000   -55,156,000 73,026,000    -21,955,000 26,462,000 -2,200,000 -8,175,000 3,377,000 19,764,000 -90,444,000 89,438,000 6,247,000    16,146,000      -31,881,000 33,198,000 
      cash and cash equivalents, beginning of period
    		0 0 276,774,000  0 0 153,298,000  0 0 104,139,000  0 0 585,578,000  0 0 99,957,000  0 0 78,228,000  0 0 132,526,000  0 0 54,126,000  0 0 35,944,000  0 0 56,984,000  0 0 37,520,000  0 0 12,515,000  0 0 10,126,000 0 0 46,168,000  0 0 26,133,000 
      cash and cash equivalents, end of period
    		-152,895,000 16,874,000 283,610,000  -1,088,000 63,001,000 184,052,000  12,309,000 51,265,000 35,545,000  -12,637,000 -104,690,000 226,751,000  28,262,000 39,075,000 66,699,000  46,692,000 23,963,000 54,589,000  25,402,000 -155,299,000 215,036,000  114,070,000 75,308,000 41,563,000  -27,598,000 -55,156,000 108,970,000  -867,000 -9,720,000 35,029,000  -2,200,000 -8,175,000 40,897,000  -90,444,000 89,438,000 18,762,000  -5,243,000 -17,646,000 26,272,000 -12,736,000 -3,768,000 25,213,000  -11,048,000 -31,881,000 59,331,000 
      see accompanying condensed notes to consolidated financial statements.
    		                                                          
      impairment of investment
    		           0                                               
      other net (gains) losses
    		 0 -5,887,000                                                        
      supplemental cash flow information:
    		                                                          
      cash paid for interest
    		  2,715,000    3,969,000  4,129,000 3,168,000 17,634,000  8,934,000 4,719,000 9,967,000  1,510,000 1,900,000 1,686,000      0 4,097,000 5,000 4,097,000 6,000 0 4,102,000  4,512,000 4,000 2,380,000                       1,175,000 
      net cash paid (received) for income taxes
    		  286,000                                                        
      non-cash investing and financing activities:
    		                                                          
      fixed assets included in accounts payable and accrued liabilities
    		  767,000    607,000  -918,000 136,000 2,252,000  3,032,000 -3,790,000 6,244,000  -3,377,000 1,063,000 7,033,000                                        
      loss on lease terminations
    		                                                          
      (gain) loss on early extinguishment of debt
    		   0 0                                                      
      impairment of indefinite-lived intangible asset
    		                                                          
      other net incomees
    		     36,000 73,000                                                    
      payment of contingent consideration
    		              -32,000,000             -1,000 -2,127,000 -2,422,000 -2,293,000 -2,241,000 -2,013,000 -2,114,000 -2,092,000 -2,067,000 -9,919,000 -1,967,000 -1,904,000 -1,992,000 -1,765,000 -1,742,000 -1,620,000 -1,713,000 -9,528,000 -1,193,000 -999,000 -790,000           
      purchases of debt and equity investments
    		                                                          
      purchase of treasury stock
    		   0 0                                                      
      proceeds from term loan a facility
    		        0 0 149,550,000                                                
      repayment of 2022 convertible senior notes
    		           0 0       0                                       
      repayment of term loan b facility
    		        0 0 -296,875,000                                                
      debt extinguishment costs
    		       0 0 0 -5,750,000                                                
      cash and cash equivalents, beginning of year
    		                                                          
      cash and cash equivalents, end of year
    		                                                          
      see accompanying notes to consolidated financial statements.
    		                                                          
      loss on early extinguishment of debt
    		       0 0 0 16,926,000         0            0 0 11,000 3,721,000             0 0 0 3,398,000        
      net cash (received) paid for income taxes
    		      -245,000                                                    
      other losses
    		       -278,000                                                   
      acquisition of flexion therapeutics, inc.
    		                                                          
      sale of equity investment
    		               0 0                                          
      purchases of equity and debt investments
    		       0 0 -2,758,000 -4,000,000 0 -250,000 0 -12,750,000 0 -2,967,000                                          
      proceeds from common stock issued under employee stock purchase plan
    		                                                          
      proceeds from term loan a facility maturing march 2028
    		                                                          
      proceeds from term loan b facility maturing december 2026
    		                                                          
      repayment of term loan b facility maturing december 2026
    		           -59,375,000 -9,375,000                                              
      repayment of term loan a facility maturing march 2028
    		                                                          
      net decrease in cash and cash equivalents
    		        12,309,000 51,265,000 -68,594,000    -358,827,000    -33,258,000                  -867,000                      
      cash paid for income taxes, net of refunds
    		        1,277,000 594,000 201,000  112,000 4,095,000 9,000  812,000 1,446,000 1,000      212,000   -18,000 0   -4,000 0   -6,000 12,000 99,000 142,000                    
      issuance of common stock from conversion of 2022 convertible senior notes
    		            0                                              
      loss on disposal of fixed assets
    		                           55,000 0 0 10,000 -6,000 109,000 1,893,000 137,000         1,000 0 149,000 8,000 1,000 0      270,000    
      loss on investment
    		            76,000 90,000 18,000        3,971,000                                    
      (gain) loss on investment
    		          -23,000                                                
      gain on disposal of fixed assets
    		           0 0 184,000 9,000                                            
      gain on investment and other non-operating income
    		                40,000                                          
      proceeds from debt component of the 2025 convertible senior notes
    		                   0                                       
      proceeds from equity component of the 2025 convertible senior notes
    		                   0                                       
      retirement of equity component of the 2022 convertible senior notes
    		                   0                                       
      net cash (used) provided by financing activities
    		                                                          
      payment of contingent consideration to myoscience, inc. securityholders
    		                0   0 0 -9,145,000 -264,000                                    
      (gain) loss on disposal and impairment of fixed assets
    		                 1,000 -11,000                                        
      (gain) loss on investment (net of stock dividend) and other non-operating income
    		                                                          
      changes in operating assets and liabilities
    		                                                          
      deferred revenue
    		                                  -205,000 -357,000 -356,000 -357,000 -356,000 -357,000 -356,000 -357,000 -356,000 -357,000 -356,000 7,678,000 -252,000 257,000         -533,000 1,000,000 
      acquisition of myoscience, inc.
    		                       992,000 0                                  
      proceeds from term loan b credit facility
    		                                                          
      repayment of 2019 convertible senior notes
    		                       0 0 0 -338,000     0                           
      conversion premium on 2019 convertible senior notes
    		                       0 0                                  
      (gain) loss on disposal of fixed assets
    		                                                          
      net cash (used in) investing activities
    		                                                          
      purchases of available for sale investments
    		                 -131,479,000 -186,653,000                                        
      sales of available for sale investments
    		                 149,006,000 145,282,000                                        
      loss on investment and other non-operating income
    		                  155,000                                        
      debt investments
    		                  -1,220,000                                        
      amortization of unfavorable lease obligation and debt issuance costs
    		                       434,000 429,000 424,000 420,000 404,000 400,000 395,000 391,000 364,000 360,000 356,000 168,000 120,000 119,000 120,000 120,000 120,000 120,000 119,000 122,000 122,000 122,000 121,000 122,000 122,000 121,000 122,000 94,000        
      loss on disposal and impairment of fixed assets
    		                   0 0 0 22,000 12,000                                   
      purchases of investments
    		                   -219,852,000 -254,401,000 347,000 -72,610,000 -98,393,000 -78,131,000 -119,272,000 -22,688,000 -180,505,000 -1,000 -52,169,000 -130,580,000 -66,735,000 -161,226,000 -94,449,000 -180,342,000 -34,425,000 -36,600,000 -53,947,000 -67,843,000                    
      sales of investments
    		                   153,103,000 59,317,000 44,682,000 50,768,000 71,103,000 85,348,000 59,830,000 103,187,000 59,586,000 101,040,000 116,798,000 127,764,000 97,751,000 141,180,000 40,568,000 42,214,000 34,457,000 37,105,000 45,140,000 54,925,000                    
      equity investment
    		                       0 0                                  
      reversal of deferred tax valuation allowance
    		                                                          
      (gain) loss on investment and other non-operating income
    		                                                          
      conversion premium on the 2019 convertible senior notes
    		                                                          
      gain on investment
    		                                                          
      payment of contingent consideration to myoscience, inc securityholders
    		                     -855,000 -4,736,000                                    
      net increase in contingent consideration liabilities
    		                        0                                  
      net decrease in accrued fixed assets
    		                     -692,000 -423,000    -37,000                                
      loss on investment (net of stock dividend) and other non-operating income
    		                                                          
      proceeds from issuance of 2022 convertible senior notes
    		                                                          
      costs for conversions of convertible senior notes
    		                                                          
      net increase in accrued fixed assets
    		                        2,345,000   32,000 -2,162,000 2,265,000 -233,000 -865,000 760,000 1,115,000 1,179,000 -604,000 477,000 -2,216,000 1,554,000                    
      depreciation of fixed assets
    		                          3,600,000  3,504,000 2,848,000 2,762,000                            
      conversion premium on convertible senior notes
    		                          -233,000                                
      depreciation of fixed assets and amortization of intangibles
    		                               3,659,000 3,361,000 3,709,000 3,104,000 3,260,000 3,278,000 3,216,000 3,165,000 3,119,000 2,830,000 2,783,000 2,743,000 2,707,000 2,392,000 2,333,000 2,603,000            
      loss on unexercised investment purchase option
    		                           0                               
      issuance of common stock from conversion of 2019 convertible senior notes
    		                               0 0 494,000 120,466,000                        
      retirement of equity component of 2019 convertible senior notes
    		                               0 -2,000 -515,000 -125,811,000                        
      proceeds from exercise of stock options
    		                            2,982,000 1,073,000 419,000 1,474,000 2,691,000 1,761,000 852,000  769,000 1,390,000 3,041,000    4,047,000          230,000 153,000 124,000 11,000 0 1,000 
      proceeds from 2022 convertible senior notes
    		                               0 0 0 345,000,000                        
      costs for conversion of convertible senior notes
    		                               0 -1,000 0 -284,000                        
      restricted cash
    		                                       0 0 0 1,509,000 320,000 339,000 -2,168,000 1,633,000 342,000 -977,000 -998,000 1,523,000   1,299,000   -2,069,000 1,314,000 
      accounts payable, accrued expenses and income taxes payable
    		                               4,817,000 -6,009,000 11,607,000 -1,056,000 6,401,000 2,967,000                      
      royalty interest obligation
    		                                       0 0 0 -276,000 -329,000 -264,000 -196,000 -181,000 -98,000           
      cash paid for interest, including royalty interest obligation
    		                                   0 1,926,000 0 1,926,000 0 1,927,000 0 2,297,000 320,000 2,290,000 332,000 2,251,000 343,000 2,311,000 262,000 584,000 1,008,000 1,114,000 1,168,000 1,166,000 1,213,000   
      repayment of debt
    		                                 -479,000 -117,712,000             0           
      accrued payment of contingent consideration
    		                                                          
      equity component of the 2022 convertible senior notes
    		                                  70,930,000                        
      adjustments to reconcile net income to net cash provided byoperating activities:
    		                                                          
      proceeds from follow-on public offering
    		                                           45,000 0              
      proceeds from exercise of stock options and warrants
    		                                       1,275,000 1,823,000   1,507,000 2,381,000 1,387,000 1,964,000 813,000 979,000 1,187,000 877,000        
      conversion of principal and equity component of convertible senior notes
    		                                       -1,000 0                  
      issuance of stock from conversion of convertible senior notes
    		                                       -1,000 0                  
      conversion of principal and premium paid on convertible senior notes
    		                                    0                      
      accounts payable and accrued expenses
    		                                      -6,227,000 7,907,000 -2,984,000 9,334,000 -4,316,000 4,078,000 4,950,000 6,757,000 -1,531,000 3,823,000 3,161,000 3,098,000 162,000        
      proceeds from convertible senior notes
    		                                               0 0 0 120,000,000        
      equity component of convertible senior notes
    		                                               0           
      loss on extinguishment of debt
    		                                        0           0       
      purchases of short-term investments
    		                                        -32,276,000 -42,984,000 -49,937,000 570,000 -87,418,000 -34,046,000 -18,946,000 -12,185,000           
      sales of short-term investments
    		                                        36,805,000 38,548,000 59,631,000 12,270,000 11,075,000              
      purchases of long-term investments
    		                                           2,000 -10,984,000              
      cash paid for income taxes
    		                                        40,000 -1,000 160,000                
      purchases of fixed assets accrued but not paid
    		                                                          
      prepaid expenses and other current assets
    		                                         660,000 372,000                
      proceeds from sales of fixed assets
    		                                                   0       
      proceeds from borrowings on long-term debt
    		                                                   0       
      value of warrants issued with debt
    		                                                   0       
      sale of short-term investments
    		                                              32,772,000 31,000,000 23,764,000 12,050,000 18,750,000        
      supplemental cash flow information
    		                                                          
      noncash investing and financing activities:
    		                                                          
      depreciation and amortization
    		                                               1,700,000 1,330,000 1,286,000 1,431,000 1,417,000 1,405,000 1,380,000 1,284,000 1,029,000 1,011,000 990,000 
      impairment of long-lived assets
    		                                                          
      purchase of fixed assets
    		                                                        -1,203,000 -832,000 
      proceeds from initial public offering
    		                                                      0 0 0 38,016,000 
      proceeds from offering
    		                                                   0       
      initial public offering costs paid in 2010
    		                                                      0 0   
      non cash investing and financing activities:
    		                                                          
      conversion of notes to common stock
    		                                                      0 0 0 51,222,000 
      conversion of preferred stock to common stock
    		                                                      0 0 0 6,000 
      value of equity premium on convertible senior notes
    		                                                 0 24,936,000        
      amortization of unfavorable lease obligation and deferred financing costs
    		                                                          
      amortization of end of term fee and warrants
    		                                                   261,000       
      accounts receivable, net of allowances
    		                                                          
      net purchases of short-term investments
    		                                                          
      amortization of deferred financing costs and unfavorable lease obligation
    		                                                          
      amortization of note discounts and warrants
    		                                                     103,000 104,000 249,000 98,000 1,193,000 
      change in royalty interest obligation
    		                                                        -816,000 -76,000 
      trade accounts receivable
    		                                                     1,253,000   755,000 -619,000 
      proceeds from sale of short-term investments
    		                                                     371,000     
      financing costs
    		                                                          
      proceeds from sale of fixed assets
    		                                                          
      purchase of short-term investments
    		                                                          
      proceeds from secondary offering
    		                                                          
      proceeds from convertible notes
    		                                                          
      proceeds from secured promissory notes and credit facility
    		                                                          
      payoff of credit facility
    		                                                          
      accrual for repurchase of intangibles
    		                                                          
      accrued fixed asset purchase
    		                                                          
      value of warrants issued with debt and beneficial conversion feature
    		                                                          
      value of warrants issued to landlord
    		                                                          
      accrued financing cost
    		                                                          
      share-based compensation
    		                                                       442,000 551,000 972,000 
      proceeds from secured promissory notes
    		                                                          
      proceeds from credit facility
    		                                                          
      amortization of other assets and unfavorable lease obligation
    		                                                        -72,000 93,000 
      deferred rent
    		                                                        8,000 13,000 
      other current assets
    		                                                         -402,000 
      initial public offering issuance costs paid in 2010
    		                                                         907,000 
      impairment loss
    		                                                          
      proceeds from issuance of preferred stock
    		                                                          
      proceeds from exercise of stock options and issuance of common stock
    		                                                          
      accrued fixed asset purchases
    		                                                          
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.